Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04729608

Recruitment Status : Terminated (There were no significant differences in median PFS between batiraxcept + paclitaxel or paclitaxel alone arms. There was no detriment to overall survival. No new safety signals were identified.)

First Posted : January 28, 2021

Last Update Posted : October 30, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

GOG Foundation

European Network of Gynaecological Oncological Trial Groups (ENGOT)

Information provided by (Responsible Party):

Aravive, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	August 4, 2023
Actual Study Completion Date :	August 4, 2023

To Top